ANAPC10 expression predicts poor prognosis in oral squamous cell carcinoma and promotes tumor growth via the PI3K/AKT/mTOR pathway.

IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2025-03-29 DOI:10.1007/s12672-025-02125-x
Jing Fang, Yanhao Duan, Yongle Qiu, Shanshan Liu, Xue Bai, Hong Cai, Meijie Zhang, Wei Liu
{"title":"ANAPC10 expression predicts poor prognosis in oral squamous cell carcinoma and promotes tumor growth via the PI3K/AKT/mTOR pathway.","authors":"Jing Fang, Yanhao Duan, Yongle Qiu, Shanshan Liu, Xue Bai, Hong Cai, Meijie Zhang, Wei Liu","doi":"10.1007/s12672-025-02125-x","DOIUrl":null,"url":null,"abstract":"<p><p>Oral squamous cell carcinoma (OSCC) is associated with high morbidity and mortality, emphasizing the need for early detection through advanced biomarkers and non-invasive methods. This study analyzed Anaphase Promoting Complex Subunit 10 (ANAPC10) mRNA expression across various cancers using multi-platform tools to assess its diagnostic potential and clinical relevance. We developed a prognostic model linking ANAPC10 expression to survival outcomes using TCGA and GTEx data, and constructed a protein-protein interaction network via GeneMANIA. Functional studies, including cell culture and various assays, demonstrated that ANAPC10 is highly expressed in OSCC and correlates with poor prognosis. ANAPC10 was found to be involved in key pathways, including NF-κB signaling and cell cycle regulation. Knockdown experiments revealed that reducing ANAPC10 expression led to decreased cell proliferation, migration, and invasion, as well as inhibition of the PI3K/AKT/mTOR signaling pathway. These findings suggest that ANAPC10 is a promising biomarker for OSCC and a potential therapeutic targetClinical Trial Number: Not applicable.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"423"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953518/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02125-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Oral squamous cell carcinoma (OSCC) is associated with high morbidity and mortality, emphasizing the need for early detection through advanced biomarkers and non-invasive methods. This study analyzed Anaphase Promoting Complex Subunit 10 (ANAPC10) mRNA expression across various cancers using multi-platform tools to assess its diagnostic potential and clinical relevance. We developed a prognostic model linking ANAPC10 expression to survival outcomes using TCGA and GTEx data, and constructed a protein-protein interaction network via GeneMANIA. Functional studies, including cell culture and various assays, demonstrated that ANAPC10 is highly expressed in OSCC and correlates with poor prognosis. ANAPC10 was found to be involved in key pathways, including NF-κB signaling and cell cycle regulation. Knockdown experiments revealed that reducing ANAPC10 expression led to decreased cell proliferation, migration, and invasion, as well as inhibition of the PI3K/AKT/mTOR signaling pathway. These findings suggest that ANAPC10 is a promising biomarker for OSCC and a potential therapeutic targetClinical Trial Number: Not applicable.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ANAPC10 的表达可预测口腔鳞状细胞癌的不良预后,并通过 PI3K/AKT/mTOR 通路促进肿瘤生长。
口腔鳞状细胞癌(OSCC)与高发病率和死亡率相关,强调需要通过先进的生物标志物和非侵入性方法进行早期检测。本研究使用多平台工具分析了晚期促进复合物亚单位10 (ANAPC10) mRNA在各种癌症中的表达,以评估其诊断潜力和临床相关性。我们利用TCGA和GTEx数据建立了连接ANAPC10表达与生存结果的预后模型,并通过GeneMANIA构建了蛋白-蛋白相互作用网络。包括细胞培养和各种检测在内的功能研究表明,ANAPC10在OSCC中高表达,并与不良预后相关。ANAPC10被发现参与关键通路,包括NF-κB信号传导和细胞周期调节。敲低实验表明,ANAPC10表达降低可导致细胞增殖、迁移和侵袭减少,并抑制PI3K/AKT/mTOR信号通路。这些发现表明ANAPC10是一种很有前景的OSCC生物标志物和潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
期刊最新文献
Endothelial dysfunction determines vascular mechanisms of metastatic progression in breast cancer. A prognostic signature of ferroptosis and lipid metabolism related genes predicts survival and immunotherapy response in hepatocellular carcinoma. Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024. Identification of prognostic signatures in pheochromocytomas and paragangliomas based on mitochondrial autophagy and ferroptosis in TCGA and GEO datasets. Therapeutic potential of diosgenin in hepatocellular carcinoma through molecular mechanisms and nanodelivery strategies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1